Literature DB >> 17554705

Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries.

Olivier Lortholary.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554705     DOI: 10.1086/518583

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  13 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

2.  International collaboration between US and Thailand on a clinical trial of treatment for HIV-associated cryptococcal meningitis.

Authors:  L O Zimmer; T L Nolen; S Pramanpol; D Wallace; M E Walker; P Pappas; P Chetchotisakd
Journal:  Contemp Clin Trials       Date:  2009-11-06       Impact factor: 2.226

3.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

4.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; H Bijie; D Dzierzanowska; N N Klimko; V Letscher-Bru; M Lisalova; K Muehlethaler; C Rennison; M Zaidi
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

5.  Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine.

Authors:  Manjunath P Pai; Hollie Bruce; Linda A Felton
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

6.  Troponoids Can Inhibit Growth of the Human Fungal Pathogen Cryptococcus neoformans.

Authors:  Maureen J Donlin; Anthony Zunica; Ashlyn Lipnicky; Aswin K Garimallaprabhakaran; Alex J Berkowitz; Alexandre Grigoryan; Marvin J Meyers; John E Tavis; Ryan P Murelli
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells.

Authors:  Wilber Sabiiti; Robin C May
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

8.  Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Maureen J Donlin; Thomas R Lane; Olga Riabova; Alexander Lepioshkin; Evan Xu; Jeffrey Lin; Vadim Makarov; Sean Ekins
Journal:  ACS Med Chem Lett       Date:  2021-04-07       Impact factor: 4.345

9.  Cross talk between the cell wall integrity and cyclic AMP/protein kinase A pathways in Cryptococcus neoformans.

Authors:  Maureen J Donlin; Rajendra Upadhya; Kimberly J Gerik; Woei Lam; Laura G VanArendonk; Charles A Specht; Neil K Sharma; Jennifer K Lodge
Journal:  mBio       Date:  2014-08-12       Impact factor: 7.867

10.  Major role for amphotericin B-flucytosine combination in severe cryptococcosis.

Authors:  Françoise Dromer; Claire Bernede-Bauduin; Didier Guillemot; Olivier Lortholary
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.